Table 1.
Intravitreal bevacizumab in the treatment of neovascular glaucoma due to proliferative diabetic retinopathy: Review of a series of five cases
| Case | Age (years) | Gender |
IOP |
Glaucoma Procedure |
BCVA |
DRP treatment | Follow-up (weeks) | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Pre IVB | 48 hours | End | Pre IVB | End | ||||||
| 1 | 64 | F | 19 | 20 | 16 | Trabeculectomy | 0.45 | 0.2 | PPV +PCG | 20 |
| 2 | 69 | F | 45 | 56 | 26 | Cyclophotocoagulation | HM | HM | None | 15 |
| 3 | 67 | F | 17 | 16 | 17 | None | 0.3 | 0.4 | PCG + CCG | 20 |
| 4 | 53 | F | 30 | 60 | 12 | Cyclophotocoagulation | HM | HM | PCG | 15 |
| 5 | 61 | M | 23 | 50 | 14 | Cyclophotocoagulation | 0.3 | 0.25 | PCG | 32 |
Abbreviations: IOP, intraocular pressure; IVB, intravitreal bevacizumab; BCVA, best corrected visual acuity; DRP, diabetic retinopathy; F, female; M, male; HM, hand motion; PPV, pars plana vitrectomy; PCG, photocoagulation; CCG, cryocoagulation.